177 Lu PSMA 617 - RadioMedixAlternative Names: 177 Lu PSMA-617
Latest Information Update: 15 Feb 2017
At a glance
- Originator RadioMedix
- Developer Excel Diagnostics and Nuclear Oncology Center; RadioMedix; University of California at Los Angeles
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Prostate cancer